Lessons From Europe: Orphan Drug Valuations Show Limits Of Cost Effectiveness
Biogen, Sanofi executives says US should learn from experience of European health technology assessment bodies as Institute for Clinical and Economic Review embarks on initiative to adapt its value framework to orphan drugs.
You may also be interested in...
The Institute for Clinical and Economic Review is launching an initiative to adapt its value assessment approach to orphan and ultra-orphan drugs, including a possible consideration of what should be a fair return on investment for manufacturers.
Orphan drugs "are falling through the cracks" of the UK’s market access process, Shire's country general manager tells the Pink Sheet and calls for urgent all-party remedial talks.
The German pricing and reimbursement authority wants better scrutiny of orphan drug designations and incentives for orphan drug development to help address the access problem.